Feedback / Questions
tozorakimab (MEDI3506) - AstraZeneca
Tozorakimab: FDA action date for COPD in Q1 2027
(AstraZeneca)
-
Sep 11, 2026 -
ERS 2026
PDUFA
•
Chronic Obstructive Pulmonary Disease • Immunology
https://www.astrazeneca.com/content/dam/az/Investor_Relations/events/AZN-2026-ERS-presentation-20260908.pdf
Sep 11, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious